Non-a, Non-b Hepatitis Virus Or Hepatitis C Virus Patents (Class 424/228.1)
  • Patent number: 10345311
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 9, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • Patent number: 9598467
    Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: March 21, 2017
    Assignee: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED
    Inventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
  • Patent number: 9175300
    Abstract: The present invention relates to a method of expressing a foreign protein in the plastid of a host cell and secreting said protein into the cytoplasm of the host cell comprising the steps of making a construct of vector linked to a coding sequence of the fusion protein comprising of signal peptide sequence followed by in-frame fusion to a foreign gene; and stably integrating said construct into the plastid genome. The present invention also relates to a method of targeting the expressed and secreted proteins from the plastids to the nucleus of the host cell. The present invention further relates to the method where the host cell is of any higher plant or any organism including single cell algae.
    Type: Grant
    Filed: November 27, 2009
    Date of Patent: November 3, 2015
    Inventors: Vanga Siva Reddy, Sadhu Leelavathi, Amit Bhardwaj
  • Patent number: 9000136
    Abstract: Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: April 7, 2015
    Assignees: Tokyo Metropolitan Institute of Medical Science, The Chemo-Sero-Therapeutic Research Institute
    Inventors: Michinori Kohara, Fukashi Murai
  • Patent number: 8945584
    Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: February 3, 2015
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
  • Publication number: 20150017207
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
  • Patent number: 8932606
    Abstract: The construction of a chimeric Pestivirus by the identification of selected regions in the 3?NTR of the viral RNA genome is described where additional RNA sequences can be stably inserted. These sequence insertions in the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3?NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: January 13, 2015
    Assignee: Life Technologies Corporation
    Inventors: Erhard Schoenbrunner, Sven-Erik Behrens
  • Publication number: 20150010504
    Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.
    Type: Application
    Filed: February 9, 2013
    Publication date: January 8, 2015
    Applicant: Lupin Limited
    Inventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20150010595
    Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
    Type: Application
    Filed: June 11, 2014
    Publication date: January 8, 2015
    Applicant: Valneva Austria GmbH
    Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
  • Patent number: 8883169
    Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Chrontech Pharma AB
    Inventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
  • Publication number: 20140328876
    Abstract: In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 6, 2014
    Inventor: Maura Ellen Campbell
  • Publication number: 20140302092
    Abstract: A nucleic acid includes the 5? untranslated region, a virus protein-coding region including the NS3 protein coding sequence, the NS4A protein coding sequence, the NS4B protein coding sequence, the NS5A protein coding sequence, and the NS5B protein coding sequence, and the 3? untranslated region of the HCV J6CF genome in that order from the 5? to 3? direction. The NS4A protein coding sequence has a mutation for substituting alanine at position 1680 with glutamic acid, as determined on the basis of the amino acid sequence of the precursor protein of the J6CF strain.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 9, 2014
    Applicants: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases
    Inventors: Takaji Wakita, Asako Murayama, Takanobu Kato
  • Publication number: 20140286995
    Abstract: A nucleic acid includes, in the following order, a 5? untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3? untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a.
    Type: Application
    Filed: August 31, 2012
    Publication date: September 25, 2014
    Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, Toray Industries, Inc., INSERM Institutut National de la Sante et de la Recherche Medicale
    Inventors: Takaji Wakita, Mohsan Saeed, Patrick Maurel, Claire Gondeau, Hiroshi Yokokawa
  • Patent number: 8834893
    Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: September 16, 2014
    Assignees: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical Science
    Inventors: Takaji Wakita, Tomoko Date, Hitoshi Takahashi
  • Patent number: 8821892
    Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: September 2, 2014
    Assignee: GlobeImmune, Inc.
    Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
  • Publication number: 20140227320
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 14, 2014
    Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Patent number: 8784837
    Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: July 22, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
  • Publication number: 20140193459
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: May 3, 2013
    Publication date: July 10, 2014
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20140193458
    Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
    Type: Application
    Filed: March 9, 2012
    Publication date: July 10, 2014
    Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
  • Patent number: 8772022
    Abstract: Hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A were developed. A deletion upstream of the inserted reporter gene sequence conferred favorable growth kinetics in Huh7.5 cells to these viruses. These reporter viruses can be used for high throughput analysis of drug and vaccine candidates as well as patient samples. JFH1-based intergenotypic recombinants with genotype specific homotypic 5?UTR, or heterotypic 5?UTR (either of genotype 1a (strain H77) or of genotype 3a (strain S52)) were also developed. The present inventors additionally developed J6/JFH1 recombinants with the 5?UTR of genotypes 1-6. These recombinants with different 5?UTRs are a useful to study the function of the 5?UTR in a genotype specific manner.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: July 8, 2014
    Assignees: Hvidovre Hospital, Kobenhavns Universitet
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Jens Bukh, Jannick Prento, Tanja Bertelsen Jensen, Jacob Bo Lademann, Yiping Li
  • Publication number: 20140186292
    Abstract: Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated DRibbles, or DRibble-loaded APCs are also disclosed. Methods are also provided for using treated cells, isolated DRibbles, or DRibble-loaded APCs to stimulate an immune response, for example in a subject. For example, DRibbles obtained from a tumor cell can be used to stimulate an immune response against the same type of tumor cells in the subject. In another example, DRibbles obtained from a pathogen-infected cell or cell engineered to express one or more antigens of a pathogen can be used to stimulate an immune response against the pathogen in the subject.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: Providence Health & Services - Oregon
    Inventor: Hong-Ming Hu
  • Patent number: 8765386
    Abstract: A method and device to detect Hepatitis C (HCV) antibodies in oral fluid is provided. This method introduces a non-antibody detection molecule that labels all classes of patient antibodies in oral fluid, followed by the specific concentration of labeled anti-HCV antibodies by selective capture in a trapping zone consisting of peptide antigens derived from the HCV genome. Signal generated by the labeled antibodies present in the trapping zone is proportional to the number of anti-HCV antibodies bound to the antigens present in the trapping zone. Presence of signal derived from the capture of antibody/detection molecule complexes in the trapping zone is indicative of past exposure to HCV.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: July 1, 2014
    Assignee: Instant Medical Diagnostics, LLC
    Inventors: Jonathan Zmuda, Lance A. Liotta, Gordon Whiteley
  • Patent number: 8765143
    Abstract: An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: July 1, 2014
    Assignee: Universite Francois Rabelais de Tours
    Inventors: Philippe Roingeard, Christophe Hourioux, Romuald Patient
  • Publication number: 20140161826
    Abstract: A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization.
    Type: Application
    Filed: April 5, 2012
    Publication date: June 12, 2014
    Inventor: Antonello Pessi
  • Patent number: 8734793
    Abstract: Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: May 27, 2014
    Assignee: Abbott Laboratories Inc.
    Inventors: Bailin Tu, Joan D. Tyner, James W. Scheffel, Michael K. White, Jeffrey M. Werneke, Robert N. Ziemann, David J. Hawksworth, Mary S. Pinkus, Robin A. Gutierrez
  • Patent number: 8728793
    Abstract: The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: May 20, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jeffrey Glenn, Nam-Joon Cho, Curtis W. Frank, Kwang Ho Cheong
  • Patent number: 8728489
    Abstract: Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: May 20, 2014
    Assignee: GlobeImmune, Inc.
    Inventors: David Apelian, Richard C. Duke, Alex Franzusoff
  • Patent number: 8715695
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: May 6, 2014
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
  • Patent number: 8703149
    Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: April 22, 2014
    Assignee: The Rockefeller University
    Inventors: Charles Rice, Matthew J. Evans, Thomas Von Hahn
  • Publication number: 20140105931
    Abstract: This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response.
    Type: Application
    Filed: May 18, 2012
    Publication date: April 17, 2014
    Applicant: EMORY UNIVERSITY
    Inventor: Arash Grakoui
  • Publication number: 20140065100
    Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Fields
  • Patent number: 8663653
    Abstract: The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analysis.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 4, 2014
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Maria Lisa Knudsen, Troels Kasper Høyer Scheel, Jens Bukh
  • Publication number: 20140056943
    Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.
    Type: Application
    Filed: September 27, 2013
    Publication date: February 27, 2014
    Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.
    Inventors: Aintzane ZABALETA AZPIROZ, Francisco BORRAS CUESTA, Jesus PRIETO VALTUENA, Pablo SAROBE UGARRIZA, Juan Jose LASARTE SAGASTIBELZA
  • Publication number: 20140023683
    Abstract: This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences.
    Type: Application
    Filed: September 8, 2011
    Publication date: January 23, 2014
    Applicants: THE UAB RESEARCH FOUNDATION, DUKE UNIVERSITY
    Inventors: George M. Shaw, Hui Li, Beatrice H. Hahn, Barton F. Haynes
  • Patent number: 8618275
    Abstract: The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6/JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6/JFH control virus. Sequence analysis of recovered 5a/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and/or NS3. Infectivity of the 5a/2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: December 31, 2013
    Assignee: Hvidovre Hospital
    Inventors: Tanja Bertelsen Jensen, Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
  • Publication number: 20130344106
    Abstract: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Inventors: ANDRE E. NEL, HYON-JEEN KIM
  • Publication number: 20130323282
    Abstract: The present invention provides a composition comprising hepatitis C virus (HCV) Envelope 2 (E2) glycoprotein, wherein the HCV E2 is substantially monomer depleted HCV E2. Also provide are methods of inducing an HCV immune response.
    Type: Application
    Filed: November 25, 2011
    Publication date: December 5, 2013
    Inventors: Heidi Drummer, Kathleen Mccaffrey, Pantelis Poumbourios
  • Patent number: 8569472
    Abstract: The present inventors developed hepatitis C virus 6a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a/2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a/2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analysis.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: October 29, 2013
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
  • Patent number: 8563706
    Abstract: The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: October 22, 2013
    Assignee: Hvidovre Hospital
    Inventors: Troels Kasper Hoyer Scheel, Judith M. Gottwein, Jannick Prento, Tanja Bertelsen Jensen, Jens Bukh
  • Publication number: 20130273101
    Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 17, 2011
    Publication date: October 17, 2013
    Applicant: EYEGENE, INC.
    Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
  • Patent number: 8541004
    Abstract: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 24, 2013
    Assignee: Transgene S.A.
    Inventors: Anne Fournillier, Genevieve Inchauspe, Jean-Daniel Abraham, Maria Dimitrova-Tchomakov, Marie Parnot
  • Patent number: 8535686
    Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: September 17, 2013
    Assignee: The MacFarlane Burnet Institute for Medical Research and Public Health Limited
    Inventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
  • Patent number: 8524868
    Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: September 3, 2013
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
  • Publication number: 20130224246
    Abstract: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 29, 2013
    Inventors: Heidi Drummer, Kathleen McCaffrey, Pantelis Poumbourios
  • Patent number: 8506969
    Abstract: Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: August 13, 2013
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
  • Publication number: 20130202554
    Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 8, 2013
    Applicant: CHRONTECH PHARMA AB
    Inventor: CHRONTECH PHARMA AB
  • Publication number: 20130183339
    Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicant: Intercell AG
    Inventor: Intercell AG
  • Publication number: 20130183376
    Abstract: The present invention provides a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes, the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer, and the peptide is bound to the surface of the liposome; a cytotoxic T lymphocyte activator containing the peptide-bound liposome; and a hepatitis C virus vaccine.
    Type: Application
    Filed: September 7, 2011
    Publication date: July 18, 2013
    Applicants: Saitama Medical University, Japan as represented by the Director-General of National Institute of Infectious Diseases, NOF Corporation
    Inventors: Toshitaka Akatsuka, Tetsuya Uchida, Maiko Taneichi, Ai Mikuma, Shoichi Yokoyama
  • Patent number: 8481050
    Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: July 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
  • Publication number: 20130171103
    Abstract: Compounds that selectively inhibit viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects and compositions comprising such Compounds are described. Also described are methods of inhibiting viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
    Type: Application
    Filed: May 26, 2011
    Publication date: July 4, 2013
    Applicant: PTC Therapeutics, Inc.
    Inventors: Thomas Davis, Jason D. Graci, Zhengxian Gu, Christopher Trotta